Anavex

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Anavex and other ETFs, options, and stocks.

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.

CEO

Christopher U. Missling

CEOChristopher U. Missling

Employees

Employees42

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2004

Founded2004

Employees

Employees42

AVXL Key Statistics

Market cap

820.29M

Market cap820.29M

Price-Earnings ratio

-16.59

Price-Earnings ratio-16.59

Dividend yield

—

Dividend yield—

Average volume

941.16K

Average volume941.16K

High today

$9.63

High today$9.63

Low today

$9.34

Low today$9.34

Open price

$9.39

Open price$9.39

Volume

646.89K

Volume646.89K

52 Week high

$14.44

52 Week high$14.44

52 Week low

$4.93

52 Week low$4.93

AVXL News

TipRanks 8h

Anavex reports new publication on mechanism with blarcamesine

Anavex (AVXL) Life Sciences reported a peer-reviewed publication in the journal iScience, ascertaining the precise autophagy mechanism of sigmar-1 receptor thro...

Benzinga 6d

Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows

Anavex Life Sciences Corp. AVXL reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment wit...

People also own

Based on the portfolios of people who own AVXL. This list is generated using Robinhood data, and it’s not a recommendation.